Gastroenteropancreatic neuroendocrine tumor

1 paper

Human trial1

Trial sponsors

RayzeBio
Company1 trialPhase 3343 people
CSPC ZhongQi Pharmaceutical Technology
Company1 trialPhase 2/3298 people
Nanjing NingQi Medicine Science and Technology
Company1 trialPhase 2/3298 people
Grupo Espanol de Tumores Neuroendocrinos
1 trialPhase 237 people

Latest

1 in 12 months

Journal of Nuclear Medicine7 Aug

Hematologic Consequences of Radiopharmaceutical Therapy: From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms

ReviewBlood and immune system

Lancet17 Dec

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Randomised trial in 302 peopleLung